About Visionary Ventures
Visionary Ventures is a venture capital firm founded in 2016. It is primarily based out of Newport Beach, United States. As of Sep 2025, Visionary Ventures has invested in 19 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across Life Sciences and Enterprise Applications sectors. Most recently it participated in the $***** Series B round of Pelage Pharmaceuticals Overall, Visionary Ventures portfolio has seen 1 IPO and 5 acquisitions including key companies like RxSight, Tarsus and Aurion Biotech. A lot of funds co-invest with Visionary Ventures, with names like Flying L Partners sharing a substantial percentage of its portfolio. Visionary Ventures has team of 14 people including 8 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Acquisitions
Deals in last 12 months
Visionary Ventures' List of Top Investments
Visionary Ventures has a portfolio of 19 companies. Their most notable investments are in Re-Vana Therapeutics and Re-Vana Therapeutics.Their portfolio spans across United States, Israel and United Kingdom. They have invested in Life Sciences, Enterprise Applications, across Series A, Series B and 2 more. Here is the list of top investments by Visionary Ventures:1. RxSight
RxSight (formerly known as Calhoun Vision) has developed an adjustable intraocular lens technology. It uses biocompatible materials called macromers which are sensitive to ultraviolet light of a certain wavelength. When irradiated by such light, the macromers undergo photopolymerization, leading to a predictable change in the shape of the lens surface.
Key facts about RxSight
- Founded Year: 1997
- Location: Aliso Viejo (United States)
- Annual Revenue: $140M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $194M
- Employee Count: 202 as on Jul 01, 2024
- Investors: HTIF, Foresite Capital and 8 Others
- Latest Funding Round: Conventional Debt, Dec 02, 2020, $*****
- Highlight: Public
2. Tarsus
Tarsus is developing a drug to treat blepharitis. The lead compound is a topical ophthalmic drug called TP-03 developed for the treatment of Demodex blepharitis will undergo Phase 2b/3 trials. The company's product pipeline also includes the development of drugs for other eye problems.
Key facts about Tarsus
- Founded Year: 2017
- Location: Irvine (United States)
- Annual Revenue: $2.89M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $60M
- Employee Count: 46 as on Dec 31, 2021
- Investors: RTW Investments, Frazier Healthcare Partners and 5 Others
- Latest Funding Round: Series B, Jan 08, 2020, $*****
- Highlight: Acquired
3. Sydnexis
Sydnexis has developed a proprietary formulation for treating myopia. The patented eye drop formulation SYD-101 is developed to reduce the myopia progression which is associated with numerous serious ophthalmic co-morbidities in children.
Key facts about Sydnexis
- Founded Year: 2014
- Location: Del Mar (United States)
- Stage: Series B
- Total Funding till date: $71.5M
- Investors: RA Capital Management, Longitude Capital and 4 Others
- Latest Funding Round: Series B, Apr 03, 2025, $*****
- Highlight: Editors' Pick
4. CorneaGen
CorneaGen focuses on developing therapeutic devices for a corneal transplant. The corneal products developed are Ampho B, Pre-Loaded Cannula, Cannula, Donor Punch, EndoSerter, and Recipient Trephine.
Key facts about CorneaGen
- Founded Year: 2017
- Location: Seattle (United States)
- Stage: Series B
- Total Funding till date: $44M
- Employee Count: 138 as on Jul 01, 2024
- Investors: Petrichor, CYwP Funds and 2 Others
- Latest Funding Round: Conventional Debt, Oct 07, 2019, $*****
- Highlight: Editors' Pick
Developer of therapeutics for hair loss treatment in men and women. It provides a topical, non-invasive small molecule pharmacological platform that can be used to activate hair follicle stem cells and promote thick hair growth.
Key facts about Pelage Pharmaceuticals
- Founded Year: 2018
- Location: Los Angeles (United States)
- Stage: Series B
- Total Funding till date: $151M
- Investors: Arch Venture Partners, Google Ventures and 3 Others
- Latest Funding Round: Series B, Sep 18, 2025, $*****
Visionary Ventures' Year-on-Year Investment Trends
Visionary Ventures has invested in 19 companies over the last 26 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 2 investments. Its most recent first time investment was in Pelage Pharmaceuticals and most recent follow-on round was in Pelage Pharmaceuticals.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 2 | 2 |
2024 | 1 | 3 | 4 |
2023 | 1 | 0 | 1 |
2022 | 2 | 1 | 3 |
2021 | 1 | 0 | 1 |
2020 | 2 | 2 | 4 |
2019 | 0 | 0 | 0 |
2018 | 1 | 1 | 2 |
2017 | 3 | 0 | 3 |
Visionary Ventures' Investments by Stage
Visionary Ventures has made 5 investments in Series A stage with an average round size of $8.66M, 4 investments in Series B stage with an average round size of $35.2M, 2 investments in Series C stage with an average round size of $67.5M and 1 investment in Seed stage with an average round size of $1.17M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Series B | 4 |
Series C | 2 |
Seed | 1 |
Note: We have considered here, only first round of investments
Visionary Ventures' Investments by Sector
Visionary Ventures has a diverse portfolio, with companies operating in the Life Sciences and Enterprise Applications. Notably, it has invested in 18 Tech companies, 16 Enterprise (B2B) companies, 7 Software companies and at least 5 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 11 |
Enterprise Applications | 2 |
Note: We have considered here, only first round of investments
Visionary Ventures' Investments by Geography
Visionary Ventures has made most investments in United States (10), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 10 |
Israel | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Visionary Ventures' recent investments
Visionary Ventures has not made any investment in 2026 so far.Here are the most recent investments by Visionary Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 18, 2025 | United States | Series B | 6732 | ||
Aug 19, 2025 | United States | Series C | 3998 | [+4] | |
Oct 08, 2024 | Israel | Series D | 5639 | [+7] | |
Sep 13, 2024 | United States | Series D | 3524 | ||
Aug 12, 2024 | United States | Series A | 6753 | [+1] |
IPOs and Publicly Listed companies in Visionary Ventures' Portfolio
1 of Visionary Ventures' portfolio company became public - RxSight. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $424MHere are Visionary Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 30, 2021 | - | - | 1189 |
Acquired companies in Visionary Ventures' Portfolio
5 companies from Visionary Ventures' portfolio have been acquired. The most recent acquisition were Aurion Biotech in Mar 2025 by Alcon.Here are Visionary Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 26, 2025 | Apr 12, 2022 | Series C | 9571 | |
Jul 07, 2022 | Jan 08, 2020 | Series B | 9981 | |
Dec 19, 2018 | Nov 07, 2017 | Series A | 4510 | |
Oct 23, 2018 | Jul 13, 2017 | Series A | 6691 | |
Jun 01, 2002 | Aug 21, 2000 | Series A | 3974 |
Team profile of Visionary Ventures
Visionary Ventures has a team of 14 members including 8 Partners, 2 Venture Partners and 2 Principals located in United States. Visionary Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Visionary Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Newport Beach | - | ||
Partner | Orange | - | ||
Partner | Santa Barbara | - | - | |
Partner | Newport Beach | - | ||
Partner | Newport Beach | - | - | |
Partner | - | - | - | |
Partner | New York City | - | - | |
Partner | Cape Coral | - | - | |
Venture Partner | Newport Beach | - | - | |
Venture Partner | Mountain Lakes | - | - | |
Principal | Wayzata | - | - |
Co-investors of Visionary Ventures
Over the past 26 years, 64 investors have co-invested in Visionary Ventures's portfolio companies. This includes funds and angels.
- Invested before Visionary Ventures: Exsight Ventures, InFocus Capital Partners and 17 others have invested in rounds before Visionary Ventures. There are 2 companies where Exsight Ventures has invested before Visionary Ventures and 2 companies where InFocus Capital Partners has invested before Visionary Ventures.
- Top Co-investors of Visionary Ventures: 30 investors entered a company along with Visionary Ventures. These include investors like Flying L Partners (2 companies).
- Invested after Visionary Ventures: A total of 15 investors have invested in Visionary Ventures's portfolio after their investments. Top Investors include Bluestem Capital (2 companies), Arch Venture Partners (1 company) and ykbioventures.com (1 company).
Recent News related to Visionary Ventures
•
•
Hair loss biotech Pelage collects $120M for Phase 3 trialsEndpoints•Oct 15, 2025•Pelage Pharmaceuticals, Main Street Advisors, Visionary Ventures, Google Ventures and 1 other
•
AP Iantrek Secures $42M Series C for AlloFlo™ Uveo Launch and Pipeline ExpansionBakersfield•Aug 20, 2025•Iantrek, Sectoral, Visionary Ventures, Civilization Ventures and 3 others
•
•
•
ONL Therapeutics Closes $65 Million in Oversubscribed Series D FinancingForexTV•Sep 13, 2024•ONL Therapeutics, Johnson & Johnson Innovation, Bios Partners, Novartis Venture Fund and 1 other
•
•
•
ONL Therapeutics closes first tranche of financing for trial of ONL1204Clinical Trials Arena•Mar 09, 2023•ONL Therapeutics, Bios Partners, Alpine Visionary Venture, Visionary Ventures and 5 others
•
Re-Vana Therapeutics Raises USD11.9M in Series A FundingFinSMEs•Nov 30, 2022•Re-Vana Therapeutics, Visionary Ventures, Exsight Ventures, InFocus Capital Partners and 4 others
